Acelyrin files IPO – is a biotech comeback on the way?

Initial public offerings in the biotech sector nosedived last year after a lot of activity in 2021, but have remained few and far between this year amid tough economic con

NICE makes J&J's Tremfya more accessible in England and Wale...

NICE has updated its recommendations for NHS use of Johnson & Johnson's IL-23 inhibitor Tremfya in the treatment of psoriatic arthritis (PsA), expanding the pool of patients eligible fo

AbbVie scores crucial phase 3 wins with Humira follow-up Sky...

AbbVie is in a race against time as US patent expiry of its Humira inflammatory diseases blockbuster looms in 2023 – but it just scored two crucial phase 3 trial victories that could help r

J&J's Tremfya to join crowded psoriatic arthritis market aft...

The FDA has approved a label extension for Johnson & Johnson’s Tremfya (guselkumab) in psoriatic arthritis, the first drug from the IL-23 class to gain a foothold in this indication. 

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthrit...

J&J filing aims Tremfya at crowded psoriatic arthritis marke...